In this context, a more detailed exploration of the potential application of exosomes in delivery and immunotherapy against tumor-draining lymph nodes (TDLNs) was presented in a study conducted by Panpan Ji et al. The researchers utilized a type of smart exosomes with engineered functionalities, including CD62L (L-selectin as a marker for TDLNs) and OX40L (a gene for activating T-cells and inhibiting regulatory T-cells) on its surface. Here, SELL is linked to neoplasm.